/PRNewswire/ ObvioHealth, a global Virtual Research Organization (VRO), today announces the launch of a first-of-its kind clinical trial in Australia, using.
Anatara Lifesciences Limited (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to announce the launch of its IBS-D Clinical Trial recruitment website.
Anatara is pleased that activities for the March quarter progressed favourably and near to anticipated timelines. There appears to be a wider appreciation of Anatara s human health initiatives with a focus on using the restoration and/or maintenance of gastrointestinal tract harmony to improve overall wellbeing.Read Full Article▸
On 14 December 2020, Anatara Lifesciences Limited (ASX:ANR) announced details of an off-market share buy-back facility (Buy-Back Facility) to buyback all of the shares held by shareholders who held unmarketable parcels of shares in the Company.Read Full Article▸
Anatara Lifesciences (ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial of its Gastrointestinal Re-Programming complementary medicine (GaRP) in participants with irritable bowel syndrome - diarrhoea subtype (IBS-D).Read Full Article▸
Anatara Lifesciences Ltd (ASX:ANR) Q3 FY21 Activities Report
Q3 FY21 Activities ReportMelbourne, April 27, 2021 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR), a developer of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 31 March 2021, along with the Company s Appendix 4C cash flow report.
Commenting on the quarter, CEO Steve Lydeamore said, Anatara is pleased to have successfully progressed two key milestones during the period - a successful trial for Anatara s proprietary enriched formulation for poultry in water, and ethics approval to start the human IBS trial. Anatara now has approval to commence two separate human trials for its Gastrointestinal Re-Programming complementary medicine (GaRP), and there appears to be a wider appreciation of the Company s human health initiatives and the potential to improve overall human wellbeing with a market different